Aoxing Pharmaceutical Company, Inc.
AOXG · OTC
6/30/2025 | 6/30/2024 | 6/30/2016 | 6/30/2015 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.35 | -0.13 |
| FCF Yield | 0.00% | -0.99% | -1.36% | 0.29% |
| EV / EBITDA | 0.00 | 0.00 | 9.16 | 14.62 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | 11.03% | 38.46% |
| Gross Margin | 0.00% | 0.00% | 75.95% | 77.67% |
| Cash Conversion Ratio | 1.00 | -0.26 | 0.55 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | 36.40% | 33.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | -303.74% | 104.01% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | 2.56 | 2.82 |
| Interest Coverage | 0.00 | 0.00 | 1.80 | 1.51 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 2.74 | 1.76 |
| Cash Conversion Cycle | 0.00 | 0.00 | 132.64 | 59.15 |